How to manage radioiodine-refractory thyroid cancer in the era of precision medicine. (PubMed, Drugs Context) - Sep 16, 2026 - "Three multi-kinase inhibitors have been approved for this indication: lenvatinib and sorafenib as a first-line option and cabozantinib as a second-line option...Thus, additional selective inhibitors have been approved: larotrectinib and entrectinib for NTRK + tumours, selpercatinib and pralsetinib for RET + tumours, and crizotinib, alectinib and lorlatinib for ALK + tumours. Such a personalized approach increases clinical benefit whilst minimizing adverse events. Future studies should focus on the combination of tyrosine kinase inhibitors and immune-checkpoint inhibitors; currently, there is no strong evidence that redifferentiation strategies add clinical benefit in terms of overall survival or progression-free survival."
Journal • Review • Oncology • Solid Tumor • Thyroid Gland Carcinoma • ALK • NTRK
|
|
Grigoris Effraimidis; Katerina Saltiki; Marina Michalaki; Olga Karapanou
|